The FDA has approved Yeztugo, the world’s first twice-a-year HIV prevention shot, proven to stop 99.9% of infections in ...

The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking ...

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV, a move the ...

FIND OUT MORE ON ELLE COLLECTIVE At this halfway point of the final Handmaid’s Tale season, there are still plenty of twists and turns, with season 6, episode 6, 'Surprise', delivering a devastating ...

Gilead Sciences' Q1 2025 earnings report shows a slight decline in product sales, primarily due to lower Veklury sales and oncology inventory issues. The HIV division remains Gilead's strongest ...

Gilead Sciences GILD will release its quarterly earnings report on Thursday, 2025-04-24. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Gilead Sciences to ...

Over in Gilead, Nick visits the Guardian he shot as ... made just waiting for a moment like this”. Janine draws them a map showing them how to get in through the Commanders’ secret elevator ...

Investing.com -- Gilead Sciences shares dropped more than 3% Wednesday following a Wall Street Journal report that the Health and Human Services Department is considering major cuts to federal ...

Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New launches like Livdelzi provide growth opportunities but are unlikely to ...

-- Gilead and Terray Will Leverage Terray’s tNova Drug Discovery Platform to Identify Small Molecule Therapeutics Against Targets of Interest -- FOSTER CITY, Calif. & LOS ANGELES--(BUSINESS WIRE ...

Gilead Sciences, the Bay Area biotech giant best known for its popular HIV drugs and COVID-19 treatment Remdesivir, is laying off 104 workers from its Foster City headquarters. The company has ...